Cargando…

Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis

INTRODUCTION: American Diabetes Association consensus guidelines emphasize individualized treatment in the management of type 2 diabetes mellitus (T2DM). Early glycemic response is a clinical marker that may predict longer term efficacy for individual patients and provide a clinical tool to enhance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fu, Haoda, Cao, Dachuang, Boye, Kristina S., Curtis, Bradley, Schuster, Dara L., Kendall, David M., Ascher-Svanum, Haya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575302/ https://www.ncbi.nlm.nih.gov/pubmed/26142890 http://dx.doi.org/10.1007/s13300-015-0119-x

Ejemplares similares

Erratum to: Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis
por: Fu, Haoda, et al.
Publicado: (2015)

Associations Between Glycemic Control, Depressed Mood, Clinical Depression, and Diabetes Distress Before and After Insulin Initiation: An Exploratory, Post Hoc Analysis
por: Ascher-Svanum, Haya, et al.
Publicado: (2015)

Erratum to: Associations Between Glycemic Control, Depressed Mood, Clinical Depression, and Diabetes Distress Before and After Insulin Initiation: An Exploratory, Post Hoc Analysis
por: Ascher-Svanum, Haya, et al.
Publicado: (2015)

Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials
por: Stauffer, Virginia, et al.
Publicado: (2009)

Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study
por: Ascher-Svanum, Haya, et al.
Publicado: (2013)

The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial
por: Chen, Lei, et al.
Publicado: (2013)

The relationship, structure and profiles of schizophrenia measurements: a post-hoc analysis of the baseline measures from a randomized clinical trial
por: Chen, Lei, et al.
Publicado: (2011)

Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study
por: Haynes, Virginia S, et al.
Publicado: (2012)

Treatment of Schizophrenia With Long-Acting Fluphenazine, Haloperidol, or Risperidone
por: Olfson, Mark, et al.
Publicado: (2007)

Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example
por: Faries, Douglas E, et al.
Publicado: (2009)

Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2005)

Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons
por: Ascher-Svanum, Haya, et al.
Publicado: (2012)

A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2004)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia
por: Faries, Douglas E, et al.
Publicado: (2009)

Predictors of Change in Adherence Status from 1 Year to the Next Among Patients with Type 2 Diabetes Mellitus on Oral Antidiabetes Drugs
por: Saundankar, Vishal, et al.
Publicado: (2016)

Empirically driven definitions of “good,” “moderate,” and “poor” levels of functioning in the treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2012)

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
por: Zhu, Baojin, et al.
Publicado: (2008)

Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan
por: Ye, Wenyu, et al.
Publicado: (2011)

Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients
por: Ascher-Svanum, Haya, et al.
Publicado: (2009)

Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2006)

Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2009)

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2011)

Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics
por: Liu-Seifert, Hong, et al.
Publicado: (2011)

Predictors of switching antipsychotic medications in the treatment of schizophrenia
por: Nyhuis, Allen W, et al.
Publicado: (2010)

Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia
por: Peng, Xiaomei, et al.
Publicado: (2011)

Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational study
por: Cuyún Carter, Gebra B, et al.
Publicado: (2011)

Effect of diabetes on caregiver burden in an observational study of individuals with Alzheimer’s disease
por: Lebrec, Jeremie, et al.
Publicado: (2016)

Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2008)

Patient perception of medication benefit and early treatment discontinuation in a 1-year study of patients with schizophrenia
por: Liu-Seifert, Hong, et al.
Publicado: (2007)

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
por: Ascher-Svanum, Haya, et al.
Publicado: (2014)

The cost of relapse and the predictors of relapse in the treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2010)

Clinical, Functional, and Economic Ramifications of Early Nonresponse to Antipsychotics in the Naturalistic Treatment of Schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2008)

Early Discontinuation and Restart of Insulin in the Treatment of Type 2 Diabetes Mellitus
por: Ascher-Svanum, Haya, et al.
Publicado: (2014)

Movement disorder profile and treatment outcomes in a one-year study of patients with schizophrenia
por: Chen, Lei, et al.
Publicado: (2013)

Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties
por: Montgomery, William, et al.
Publicado: (2012)

Baseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence
por: Kelin, Katarina, et al.
Publicado: (2010)

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians
por: Chen, Jian, et al.
Publicado: (2011)

Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2012)

Item response analysis of the Positive and Negative Syndrome Scale
por: Santor, Darcy A, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_01117mh8r5n4e9gr091l3gc0p6